论文部分内容阅读
目的 探讨EGF、EGFR和PCNA表达与胰腺癌临床病理学特征以及预后的关系。方法 用免疫组化法检测 70例胰腺癌和 8例正常胰腺组织EGF、EGFR与PCNA表达。结果 胰腺癌组织中EGF、EGFR表达阳性率分别为 47 1%和 6 1 4% ,PCNALI为 31 8%± 18 3% ,正常胰腺组织表达较弱。三者表达与胰腺癌分化程度有关(P <0 0 5或P <0 0 1) ,但与肿瘤大小、部位、淋巴结转移和临床分期无关。EGF阳性病例术后平均中位生存期与阴性病例无明显差别 (P >0 0 5 ) ,而EGFR阳性病例较阴性病例明显缩短 (P <0 0 1)。PCNALI与胰腺癌术后生存期呈明显负相关 (r=- 0 47,P <0 0 1) ,PCNALI≤ 33 2 %组术后生存期与 >33 2 %组相比具有明显差异 (P<0 0 5 )。结论 胰腺癌组织EGFR和PCNA检测对判定肿瘤恶性程度和估计预后具有一定临床意义。
Objective To investigate the relationship between the expression of EGF, EGFR and PCNA and the clinicopathological features and prognosis of pancreatic cancer. Methods Immunohistochemistry was used to detect the expression of EGF, EGFR and PCNA in 70 cases of pancreatic cancer and 8 cases of normal pancreas. Results The positive rates of EGF and EGFR expression in pancreatic cancer tissues were 47 1% and 61.4%, respectively, and PCNALI was 31 8%± 18 3%. Normal pancreas tissue expression was weak. The three expressions were related to the degree of differentiation of pancreatic cancer (P < 0.05 or P <0 01), but not related to tumor size, location, lymph node metastasis and clinical stage. The median postoperative survival of EGF-positive cases was not significantly different from that of negative cases (P > 0.05), while the positive cases of EGFR were significantly shorter than those of negative cases (P <0 01). There was a significant negative correlation between PCNALI and postoperative survival of pancreatic cancer (r = - 0 47, P <0 01). The postoperative survival of PCNALI <33 2% group was significantly different from that of> 33 2% (P < 0 0 5 ). Conclusions The detection of EGFR and PCNA in pancreatic cancer has certain clinical significance in determining the degree of malignancy and estimating the prognosis.